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comparison between the device and new anticoagulants in
terms of follow-up, patient characteristics and time in ther-
apeutic range. Also, the study is not powered enough to
answer questions in specific subgroups (e.g. patients with
prior history of TIA/stroke).
We believe that further studies with large number and long
term follow-up will clarify whether use of such devices can be
generalized. If approved, this therapy will not only revolu-
tionize the management of AF (by minimizing issues like
major bleed, drug interruption for surgical procedures and
compliance) but also design studies targeting patients deemed
in eligible to oral anticoagulation.r e f e r e n c e s
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Background: Although balloon pulmonary angioplasty
(BPA) for inoperable patients with chronic thromboembolic
pulmonary hypertension was first reported over a decade ago,
its clinical application has been restricted because of limited
efficacy and complications. We have refined the procedure of
BPA to maximize its clinical efficacy.
Methods and results: Sixty-eight consecutive patients
with inoperable chronic thromboembolic pulmonary
hypertension (CTEPH) underwent BPA. We evaluated pul-
monary artery diameters and determined the appropriate
balloon size by using intravascular ultrasound. We per-
formed BPA in a staged fashion over multiple, separate
procedures to maximize efficacy and reduce the risk of
reperfusion pulmonary injury. A total of 4 (2e8) sessions
were performed in each patient, and the number of vessels
dilated per session was 3 (1e14). The World Health Organ-
ization functional class improved from 3 to 2 (p < 0.01), andmean pulmonary arterial pressure was decreased from
45.4  9.6 to 24.0  6.4 mm Hg (p < 0.01). One patient died
because of right heart failure 28 days after BPA. During
follow-up for 2.2  1.4 years after the final BPA, another
patient died of pneumonia, and the remaining 66 patients
are alive. In 57 patients who underwent right heart cathe-
terization at follow-up, improvement of mean pulmonary
arterial pressure was maintained (24.0  5.8 mmHg at
1.0  0.9 years). Forty-one patients (60%) developed reper-
fusion pulmonary injury after BPA, but mechanical ven-
tilation was required in only 4 patients.
Conclusions: Our refined BPA procedure improves clinical
status and hemodynamics of inoperable patients with chronic
thromboembolic pulmonary hypertension, with a low mor-
tality. A refined BPA procedure could be considered as a
therapeutic approach for patients with inoperable chronic
thromboembolic pulmonary hypertension.1. Perspective
Pulmonary endarterectomy is the only potentially curative
treatment for CTEPH. However, nearly one-third patients of
CTEPH are not fit for this procedure because of various rea-
sons. Although vasodilator therapy such as epoprostenol has
been tried in such cases, they have very limited efficacy in
terms of functional class or hemodynamics. Considering the
highmortality of such patients when untreated an alternative
therapeutic option is required. It is in this context that BPA can
play some role.
BPA for a patient with CTEPH was first reported in 1988. In
2001, Feinstein et al reported improvement in hemodynamics
in 18 inoperable cases of CTEPH. However, even after more
than 20 years after the first report of BPA, it is still not widely
accepted as a therapeutic option for inoperable patients with
CTEPH because of the following reasons: 1) insufficient
improvement in hemodynamics after BPA, 2) inaccurate esti-
mate of balloon size based only on angiographic findings
thereby leading to pulmonary artery rupture and 3) high inci-
dence of pulmonary reperfusion injury andpulmonary edema.
The present study has tried to overcome these limitations
by refining BPA by use of the following measures: 1) use of
IVUS to provide more accurate estimates of the diameters of
target pulmonary arteries, thereby preventing rupture of
pulmonary arteries to a great extent, 2) BPA done in a staged
fashion over multiple procedures to reduce the risk of pul-
monary reperfusion injury while still achieving an effective
therapeutic result. Also, in this study, a soft-tipped 6F guiding
catheter, a thinner 0.014-inch wire and a low profile balloon
were used, which potentiated the opening of completely
obstructed lesions with a lower risk of perforation. All these
armamentarium are commercially available and this proce-
dure can be performed in any catheterization laboratory.
After determination of the vessel diameter with IVUS, initial
dilatation was done with a 2 mm balloon and the diameter of
the balloon was gradually increased to a maximum size of
not more than 90% of the original vessel diameter. This
avoided rupture and dissection of the pulmonary artery. The
procedure was repeated in multiple sessions until a sufficient
amount of stenosis were dissolved. The more segments
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achieved. The mean PA pressure was reduced >20 mmHg to
<25 mmHg. Though reperfusion pulmonary injury developed
in 60% patients after BPA, only 6% patients (as compared to
17% in a previous study) required mechanical ventilatory
support. I/V epoprostenol, methylprednisolone and NIPPV
have all been tried to reduce it, but all have failed to do so. An
attempt has been made, however, to reduce this complica-
tion by not dilating >2 vessels at the initial BPA and perform
it in a staged fashion over multiple, separate procedures and
also by doing limited BPA only within a single lobe at a time.
The reduction in this complication with time also indicates a
role for learning curve and proficiency of operators per-
forming BPA.
Considering the fact that reperfusion injury is unavoidable
despite best efforts, postprocedural intensive monitoring of
hemodynamics and oxygenation at least for 72 h is necessary,
even if the patient appears to be free from pulmonary injury
after BPA.
In my opinion, refined BPA using the technique as in this
study, can be used to remove stenosis in distal pulmonary
arteries to obtain a substantial decrease in PA pressure and
to improve WHO functional class in patients who are not
candidates for either endarterectomy or lung trans-
plantation. It is not that complicated procedure and it can be
done by interventional cardiologist doing coronary inter-
vention. However, there is definitely a learning curve and
acquiring BPA technique and training is necessary, which is
the case as with any procedure. Though the numbers in this
study are small (68 patients) and follow-up was for 2.2  1.4
years only, it has offered a ray of hope to inoperable patients
and further larger studies with longer follow-up and
randomized trials versus medical therapy is the need of the
hour for such patients.
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Rate control is often the therapy of choice for permanent
atrial fibrillation. The RACE II study was the first to evaluate
the relative efficacy of strict rate control (resting heart
rate< 80 bpmand duringmoderate exercise<110 bpm) versus
lenient rate control (resting heart rate <110 bpm) in patients
with permanent AF. The study demonstrated that lenient rate
control was not only easier to achieve but was non-inferior to
strict rate control in reducing symptoms, improving thequality of life, exercise tolerance and survival. However, an
important limitation was the marked discrepancy in the
number of patients achieving target heart rate (THR), in the
two groups. While only 67% achieved THR in the strict rate
control group, almost all (98%) achieved THR in the lenient
rate control group.
Since this could have influenced the outcome in favor of
lenient rate control, the present post hoc analysis evaluated
differences in outcomes in patients with successful strict
(n¼ 203), failed strict (n¼ 98), and lenient rate control (n¼ 307).
Patients in the strict rate control group who failed to achieve
one of the heart rate criteria were classified as failed strict
while the remaining patients were classified as successful
strict rate control.
Nearly 80% of patients in the failed strict group had resting
heart rate >80 bpm at the end of dose-adjustment phase.
Reasons for failure to achieve strict rate control included drug-
related adverse events in 25% and inability to achieve THR
with drugs in another 20% patients.
Clinical characteristics and echocardiographic parameters
(including left atrial and left ventricular dimensions and
baseline EF) were similar amongst the three groups. Mean
dosages of rate control drugs (beta blockers, verapamil and
digoxin) as well as use of drug combination was significantly
higher in successful strict and failed rate control as compared
to lenient rate control groups. The number of additional hos-
pital visits at 1 and 2 years of follow upwere significantlymore
common in the successful strict and failed strict compared
with the lenient group while there was no difference in
additional visits between the successful strict and failed strict
groups.
The primary outcome (composite of death from car-
diovascular causes, hospitalization for heart failure, and
stroke, systemic embolism, bleeding, and life-threatening
arrhythmic events), all-cause mortality and quality of life
scores were not significantly different amongst patients with
strict, failed strict or lenient rate control. Separate analysis of
patients with EF <40% also revealed no differences in the
primary outcome. Whether use of more aggressive measures
to achieve strict rate control or longer follow up would reveal
any outcome differences remains to be studied further.
The study confirms that it is often difficult to achieve strict
heart rate control in patients with AF with currently available
anti-arrhythmic drugs. Not only do these patients require
higher dosages of drugs and drug combinations, but the
number of additional hospital visits is also more. Despite
achieving pre-specified target heart rate, there was no differ-
ence in outcome between successful and failed strict rate
control. Therefore a strategy of lenient rate control may con-
tinue to be the preferred strategy in patients with permanent
AF. However in patients with intolerable rate related symp-
toms or onset of tachycardiomyopathy, lower heart rate tar-
gets may be reasonable.
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